Literature DB >> 7722855

Impact of simulating borderline personality disorder on the MMPI-2: a costs-benefits model employing base rates.

H J Sivec1, M J Hilsenroth, S J Lynn.   

Abstract

This investigation extends current work on the impact of role-specific response sets on dissimulated Minnesota Multiphasic Personality Inventory-2 (MMPI-2; Butcher, Dahlstrom, Graham, Tellegen, & Kaemmer, 1989) profiles. Specifically, one group of subjects was given specific symptom information and instructed to simulate borderline personality disorder on the MMPI-2. This dissimulation performance was compared to a clinical comparison group of clients diagnosed with borderline personality disorder, a group of subjects instructed to simulate major depression, and a group of subjects who responded honestly to the MMPI-2. In both simulating conditions, subjects produced significantly higher elevations on a majority of clinical and validity scales than the clinical comparison group. A rigorous evaluation of the F scale was conducted to provide a range of predictive values for different F scale cutting scores for detecting malingering. Sensitivity, specificity, and positive and negative predictive power were computed for this range of F scale values. A similar analysis was conducted for the Borderline Personality Disorder Scale (BPDsc) of Morey, Waugh, and Blashfield (1985). These results are integrated with extant research. A costs-benefits model is proposed for employing F scale cutting scores in clinical situations with different base rates of malingering.

Entities:  

Mesh:

Year:  1995        PMID: 7722855     DOI: 10.1207/s15327752jpa6402_9

Source DB:  PubMed          Journal:  J Pers Assess        ISSN: 0022-3891


  1 in total

1.  Psychological features of abstinent heroin users before and after rehabilitation in Saint Petersburg, Russia.

Authors:  Timofey Galankin; Dmitry Lioznov; Svetlana Nikolaenko; Louise-Anne McNutt; Emily Leckman-Westin; Perry F Smith
Journal:  BMC Res Notes       Date:  2018-08-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.